SCHEMBL6491302

SCHEMBL6491302

COC(=O)[C@@H](Cc1cccc(O)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 1/20 0.59
NLRP3 Q96P20 1/20 0.55
CTSS P25774 8/20 0.54
CTSK P43235 7/20 0.54
CTSB P07858 4/20 0.54
CTSL P07711 2/20 0.53
ACE P12821 1/20 0.52
EPHX2 P34913 1/20 0.48
MDM4 O15151 1/20 0.47
MDM2 Q00987 1/20 0.47
PPARA Q07869 1/20 0.47
CACNA1B Q00975 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.46
TACR1 P25103 1/20 0.45
PTPN1 P18031 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352344 1.00 KLK5 (0.59) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL30765043 1.00 KLK5 (0.59) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL2352336 1.00 KLK5 (0.59) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL29543144 1.00 KLK5 (0.59) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL15856094 0.94 CTSS (0.55) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL15856124 0.94 CTSS (0.55) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL12643835 0.90 CTSS (0.52) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL16459766 0.89 CTSS (0.51) KLK5NLRP3CTSSCTSKCTSB
SCHEMBL20905929 0.89 CTSS (0.56) KLK5CTSSCTSKCTSBCTSL
SCHEMBL14576685 0.89 CTSS (0.56) KLK5CTSSCTSKCTSBCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067665-A1 SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY AVIKO RADIOPHARMACEUTICALS LLC (US) 2024-02-29 US disclosed
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 KLK5 4614/4885NLRP3 3635/4885CTSS 4294/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 KLK5 4605/4885NLRP3 3646/4885CTSS 4072/4885
US-20240067665-A1 SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY NME2, BTD, BLVRB KLK5 2119/4885NLRP3 4825/4885CTSS 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.